Shareholder Investigations Unfold for Cytokinetics and Molina Healthcare
Cytokinetics, Inc. and Molina Healthcare, Inc. are under scrutiny as investigations into potential breaches of fiduciary duties by their respective officers and directors have emerged. The investigations, led by the Grabar Law Office, focus on whether these corporate leaders misled shareholders and failed to uphold their responsibilities.
Grabar Law Office announced its investigation into Cytokinetics, Inc. (NASDAQ: CYTK) on December 9, 2025. The inquiry specifically addresses allegations that certain executives provided materially false statements regarding the company’s New Drug Application (NDA) for aficamten. Investors who purchased shares prior to December 27, 2023, and continue to hold them, may be eligible to seek corporate reforms and reimbursement at no cost.
On March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration (FDA) would not convene an advisory committee meeting to review its NDA for aficamten. This announcement followed the FDA’s extension of the Prescription Drug User Fee Act action date from September 26, 2025, to December 26, 2025, to review a Risk Evaluation and Mitigation Strategy (REMS) that the company failed to include in its original filing. CEO Robert I. Blum later revealed that the company had opted to submit the NDA without a REMS, relying instead on labeling and voluntary educational materials. These disclosures reportedly led to significant financial harm for the company and its shareholders.
Shareholders of Molina Healthcare, Inc. (NYSE: MOH) are also encouraged to participate in an investigation initiated by Grabar Law Office. Similar to Cytokinetics, the inquiry examines whether executives failed to disclose crucial information regarding the company’s financial health. Investors who acquired shares prior to February 5, 2025, may seek corporate reforms and other remedies without any cost.
The underlying allegations entail that Molina Healthcare’s leadership did not reveal adverse facts concerning their medical cost trend assumptions. It was claimed that the company faced a disconnect between premium rates and medical costs, and its financial guidance for fiscal year 2025 was likely to be significantly reduced.
Furthermore, Grabar Law Office is investigating Synopsys, Inc. (NASDAQ: SNPS), where shareholders may have been misled during the acquisition of Ansys, Inc. Allegations suggest that Synopsys executives inflated the company’s revenue and profit growth figures through unsustainable practices. If investors bought Synopsys shares before December 4, 2024, or received them in exchange for Ansys stock, they can also engage in the ongoing investigation.
On September 9, 2025, Synopsys revealed disappointing Q3 results, which indicated an 8% year-over-year decline in design IP revenue. The company acknowledged that several anticipated IP deals had not materialized, resulting in a swift market reaction that saw stock prices plummet by 35.8%, erasing billions in market capitalization.
In addition, the Grabar Law Office is involved in a class action lawsuit concerning WEBTOON Entertainment Inc. (NASDAQ: WBTN). The U.S. District Court for the Central District of California recently allowed the case to proceed, rejecting a motion to dismiss by the defendants. The court found that allegations of misleading investors regarding the Monthly Active Users (MAU) metric at the time of its IPO were credible.
Investors in both Cytokinetics and Molina Healthcare are encouraged to review their eligibility for participation in the investigations. For additional information, individuals can visit the Grabar Law Office’s website, or directly contact Joshua Grabar at [email protected] or by phone at 267-507-6085.
